Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment.

已完结 10 由六月六发布于 2025/10/28 9:02:48

DOI:10.1080/13543784.2025.2510673
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1080/13543784.2025.2510673

Taylor & Francis

Abstract：Background: BI 764198 could reduce podocyte injury in focal segmental glomerulosclerosis (FSGS).Research design and methods: Four Phase 1 BI 764198 trials: single rising dose (SRD) and multi

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Taylor & FrancisA randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men.